High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 5, 2002, Pages 577-581

  Abbas, Zaigham ^a   Hamid, Saeed ^a   Tabassum, Shaesta ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Daily interferon; Hepatitis C; Ribavirin; Treatment na ve patients

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RNA ANALYSIS; SEROTYPING; VIRUS TYPING;

EID: 0036302229     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02711.x     Document Type: Article

References (25)

1. National Institute of Health Consensus Development Conference Panel Statement: Management of hepatitis C
2. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Randomized double blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
5. Long term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C
6. Permanent response to alpha interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum
7. Loss of serum HCV-RNA at four weeks of interferon alpha therapy is associated with more long term response in patients of chronic hepatitis C
8. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C
9. Hepatitis C kinetics: Mathematical modeling of viral response to therapy
10. Hepatitis C viral dynamicsin vivo and the antiviral efficacy of interferon-alpha therapy
11. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype
12. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial
13. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load
14. Principles of interferon induction therapy
15. Foie et voie biliare. Point de vue. Quelle classification pour les hepatites chroniques?
16. Viral kinetics and mathematical models
17. Dynamics of hepatitis C viremia following interferon-alpha administration
18. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
19. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b
20. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
21. Peginterferon alfa-2a in patients with chronic hepatitis C
22. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
23. Peginterferon alfa-2B plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial
24. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis
25. Hepatitis C virus genotypes and chronic liver disease in Pakistan